6. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655–2666.
7. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014 Apr;19(3):353–359.
8. Ebata S, Yoshizaki A, Oba K. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): A double-blind, investigator-initiated, randomized, placebo-controlled trial. Lancet Rheumatol. 2021 Jul;3(7):E489–E497.
9. Battafarano DF, Ditmyer M, Bolster MB, et al. 2015 American College of Rheumatology workforce study: Supply and demand projections of adult rheumatology workforce, 2015–2030. Arthritis Care Res (Hoboken). 2018 Apr;70(4):617–626.
10. Garneau KL, Iversen MD, Tsao H, et al. Primary care physicians’ perspectives towards managing rheumatoid arthritis: Room for improvement. Arthritis Res Ther. 2011;13(6):R189.
11. Ferucci ED, Templin DW, Lanier AP. Rheumatoid arthritis in American Indians and Alaska Natives: A review of the literature. Semin Arthritis Rheum. 2005 Feb;34(4):662–667.
12. Arora S, Thornton K, Komaromy M. Demonopolizing medical knowledge. Acad Med. 2014 Jan;89(1):30–32.
